Sever's disease is heel pain caused by the Achilles tendon pulling on the growing heel bone — driven by calf tightness and heel impact. The Orthopaedic Sleeve reduces both forces, with University of Queensland-validated biomechanical data to back it up.
Sever's disease happens when a child's heel bone is growing fast but the Achilles tendon hasn't caught up yet. The tendon pulls constantly on a soft, vulnerable spot at the back of the heel — the growth plate. Every step, every sprint, every jump adds another tug. Eventually the heel gets sore, swollen, and painful enough to stop a child in their tracks mid-season.
Posterior heel pain that starts during activity and worsens through the session — then stiffens overnight and hurts first thing in the morning.
Squeezing the heel from both sides reproduces the pain. This is the classic clinical sign — it localises the pain exactly to the growth plate at the back of the heel.
During a growth spurt, the heel bone is growing quickly but the tendon is lagging behind — creating a temporary tug-of-war. This makes the back of the heel the weakest link in the whole system, and it gets overloaded.
Without load management, children progressively reduce activity. The standard advice — rest — is effective but devastating for developing athletes.
The back of the growing heel bone — the exact site of pain in Sever's — is directly offloaded by three of the Orthopaedic Sleeve's four validated mechanisms.
Sever's disease is a loading problem at one specific spot: the back of the growing heel. Three of the four independently measured mechanisms directly reduce the forces hitting that exact spot. The fourth reduces how many times per day it gets hit.
The Achilles tendon attaches directly into the sore spot at the back of the heel — the growth plate. Every contraction of the calf muscle pulls on this exact point. A University of Queensland muscle model confirmed peak Achilles tendon force was reduced by up to 8.1% while wearing the Orthopaedic Sleeve — directly reducing the tugging force on the growth plate with every step.
This is the primary pathological driver of Sever's disease — addressed directly.
A 5.1% reduction in heel contact time means each stride hits the ground for slightly less time, reducing the impact at the sore heel. For a child who refuses to stop training — which is most of them — this cumulative reduction across thousands of steps per session adds up to meaningful protection.
Less contact time = less repetitive pounding on the sore heel with every step.
Gastrocnemius and soleus are the muscles that generate the Achilles traction force. EMG measurements confirmed an up-to 32% reduction in medial gastrocnemius activation during standing balance (p=0.002), and -21.9% at toe push-off on the trail leg. Less muscle contraction means less pull through the Achilles — less traction at the apophysis. The brace addresses the problem at its muscular source.
Reducing calf output reduces the traction force driving apophysitis.
A 14% reduction in the peak knee extension moment was also recorded. It is an incidental finding from the same session rather than a design target, and no claim is made on it. What does bear on the heel is the direct Achilles and heel impact reductions — stacking the protection from three different directions simultaneously.
Systemic load redistribution compounds the direct calcaneal offloading.
The Orthopaedic Sleeve's data was gathered using VALD's human performance technology alongside University of Queensland laboratory equipment — the same systems used by elite sports organisations worldwide. This isn't self-reported comfort data. It's instrumented science.
Custom orthotic prescription is a well-established clinical approach for Sever's disease. The Orthopaedic Sleeve takes a different route — direct biomechanical load reduction, independently validated at the University of Queensland, at a more accessible price.
Comparison reflects publicly listed rates for custom orthotic prescription and specialist consultation in Australia (approximate, 2025). Actual costs vary by clinic and individual needs. Orthotic therapy is a clinically supported pathway for Sever's disease; this comparison is offered to help families understand the range of options available and the differing mechanisms involved.
Independent biomechanical study using 3D motion capture, instrumented force plates, surface EMG, and Hill-type muscle modelling. Conducted in partnership with VALD. Human Research Ethics Approval: #2024/HE001495. Results statistically significant at p < 0.05 unless otherwise stated.
Put on the Orthopaedic Sleeve before sport or physical education. The back of the heel takes the most stress at first foot contact — the sleeve needs to be on before activity starts, not after the pain kicks in.
Ensure the heel cup seats fully without slipping. Correct heel contact is essential — the device modifies calcaneal contact time only when the sleeve is properly positioned and tensioned.
Tension should feel supportive but not restrict ankle forward-bend. Young athletes should be able to perform all normal sport movements — the brace works with natural gait, not against it.
Football, basketball, running, PE — any repetitive heel-striking activity. The biomechanical benefit accumulates over thousands of strides, so consistent wear during sport is key.
The Orthopaedic Sleeve is an active load-management device, not a night splint. Remove overnight and allow normal skin recovery. Consistent daytime wear is where the cumulative benefit is built.
independently tested Achilles and heel load reduction. $90AUD, ships Australia-wide. A simpler path back to the field.
Free shipping within Australia · Secure checkout
ARTG Registered Class I Medical Device. Validated by the University of Queensland using EMG, 3D motion capture, and VALD force analysis.
One sleeve. Four biomechanical mechanisms. Seven lower limb conditions. $90AUD with free shipping Australia-wide.
We have 14 verified reviews across the other conditions the sleeve is used for, but nobody has yet written one specifically about Sever's disease. We would rather tell you that than show you a review about something else and let you assume. If you have used the sleeve for this, we would like to hear from you.
The pattern to look for. An active child, most often between about 8 and 13, with pain at the back or underside of the heel that warms up in the first few minutes of sport and then becomes genuinely sore as the session goes on or afterwards. Squeezing the sides of the heel bone reproduces it. In the absence of trauma there is usually not much else to find — no swelling, no single moment of injury, nothing dramatic on examination. That combination is the signal. This is a clinical observation from our own practice rather than a validated diagnostic rule, and any child with night pain, pain at rest, a limp that does not settle, or a clear traumatic onset needs a proper work-up rather than a pattern match.
On the conditions we name. Where this site says the Sleeve has been used for a condition, that comes from direct clinical contact — those people were patients, and the response was seen in clinic and recorded at the time. It is clinical observation, not trial data, and it is offered as exactly that.
About the study
The Orthopaedic Sleeve was independently tested at the University of Queensland School of Biomedical Sciences, under Human Research Ethics approval #2024/HE001495, with the final report delivered in June 2025. Measurement used 3D motion capture, instrumented force plates, surface EMG and Hill-type musculoskeletal modelling, on VALD research-grade instrumentation. In-shoe plantar pressure mapping was measured separately with Paromed sensors.
It is a commissioned validation study, not a peer-reviewed publication and not a clinical trial — we paid for it, it was carried out by researchers in our field under formal ethics approval, and the full report is published on this site for anyone to read and check. The participants were healthy adults, so every figure describes the immediate mechanical effect of wearing the device rather than a treatment outcome in a patient.
Individual maxima are quoted with the group mean beside them because the response varied considerably between participants — which is the ordinary finding for mechanical interventions at the ankle, and the reason a responder trial rather than a group mean is the right way to judge one. No sham-controlled trial of this device in any condition exists yet.
